Apellis Pharmaceuticals Bundle
What is Apellis Pharmaceuticals's History?
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing treatments for complement-driven diseases. A key milestone was the 2023 FDA approval of SYFOVRE for geographic atrophy, a major cause of blindness.
Founded in 2009, the company aimed to create groundbreaking therapies for serious conditions across various medical fields. Their commitment to innovative science has driven their growth.
The company's journey includes the development of SYFOVRE and EMPAVELI. In 2024, these therapies achieved $781.4 million in revenue, showing 97% growth year-over-year. This success highlights their impact in complement-targeted therapies. Learn more about their market position through Apellis Pharmaceuticals Porter's Five Forces Analysis.
What is the Apellis Pharmaceuticals Founding Story?
Apellis Pharmaceuticals history began on September 25, 2009, with its founding by Cedric Francois, M.D., Ph.D., and Pascal Deschatelets, Ph.D. Their scientific backgrounds in immunology and drug development set the stage for the company’s mission to target the complement system.
Apellis Pharmaceuticals Founding Story
Apellis Pharmaceuticals was established with a clear vision to address unmet medical needs by focusing on the complement system, a critical component of the immune response. The founders, including Dr. Cedric Francois and Dr. Pascal Deschatelets, recognized the therapeutic potential in modulating this system for various autoimmune and inflammatory diseases.
- Apellis Pharmaceuticals founding date: September 25, 2009
- Key founders: Cedric Francois, M.D., Ph.D., and Pascal Deschatelets, Ph.D.
- Initial focus: Targeting the complement system for autoimmune and inflammatory diseases
- Early funding: Secured $32.5 million in Series A financing in 2009
- Lead drug candidate development: APL-2 (pegcetacoplan)
The Apellis Pharmaceuticals background is rooted in the identification of a significant therapeutic gap in treating conditions driven by the complement system. The company's initial business model was designed to discover, develop, and commercialize novel treatments for these diseases. In its early years, Apellis Pharmaceuticals received crucial support through a Series A financing round, which provided $32.5 million from investors Vatera Healthcare Partners and Morningside Capital. This capital infusion was vital for advancing their pioneering drug candidate, APL-2, which later became known as pegcetacoplan, a molecule designed to regulate the immune system by inhibiting a key protein involved in inflammation. This early investment marked a significant step in the Apellis Pharmaceuticals growth story and its journey toward bringing innovative therapies to patients. Understanding the Growth Strategy of Apellis Pharmaceuticals provides further insight into their development path.
Apellis Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Apellis Pharmaceuticals?
Apellis Pharmaceuticals began its journey with a strategic focus on developing innovative therapies for rare diseases. The company quickly established a significant research and development presence, relocating to the biotechnology hub of Waltham, Massachusetts, in 2010.
Apellis Pharmaceuticals Founding and Early Development
Apellis Pharmaceuticals was founded with a clear mission to address unmet medical needs through its complement inhibitor platform. The company's early years were marked by a concentrated effort to build its research capabilities and advance its lead candidate, APL-2 (pegcetacoplan).
Securing Funding for Growth
By 2016, Apellis had secured $47.1 million in venture capital, following an earlier attempt at an IPO. This funding was crucial for advancing its pipeline, particularly APL-2, into multiple clinical trials for rare conditions.
Key Milestones: IPO and Expansion
A pivotal moment in the Apellis Pharmaceuticals history was its successful Initial Public Offering (IPO) in 2015, which raised $150 million. This capital infusion significantly bolstered the company's ability to fund its extensive clinical development programs.
Continued Financial Growth and Leadership
The company's financial trajectory continued upward, accumulating a total of $213 million across 13 funding rounds by July 2025, including a substantial $329 million Post IPO round in May 2020. Cedric Francois has been instrumental as CEO since September 2009, guiding the company's strategic focus on complement inhibition and aligning with the Mission, Vision & Core Values of Apellis Pharmaceuticals.
Apellis Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Apellis Pharmaceuticals history?
Apellis Pharmaceuticals has achieved significant milestones, including the FDA approval of EMPAVELI in 2021 for PNH and SYFOVRE in 2023 for geographic atrophy, marking advancements in complement-targeted therapies. The company's financial performance in 2024 showed substantial growth, with total revenues reaching $781.4 million.
| Year | Milestone |
|---|---|
| 2021 | FDA approval of EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). |
| 2023 | FDA approval of SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration. |
| 2024 | Reported total revenues of $781.4 million, a 97% year-over-year increase. |
| July 28, 2025 | Received U.S. FDA approval for EMPAVELI for C3 glomerulopathy (C3G) and primary immune complex-mediated glomerulonephritis (IC-MPGN). |
Apellis Pharmaceuticals has pioneered new therapeutic classes, notably with EMPAVELI as the first targeted C3 therapy and SYFOVRE as the first FDA-approved treatment for geographic atrophy. These innovations represent significant advancements in addressing complement-mediated diseases.
Targeted C3 Therapy
EMPAVELI's approval marked the introduction of the first new class of complement medicine in 15 years, specifically targeting C3.
Geographic Atrophy Treatment
SYFOVRE became the first and only FDA-approved treatment for geographic atrophy, addressing a significant unmet need in age-related macular degeneration.
Expansion into Rare Kidney Diseases
The 2025 FDA approval for EMPAVELI in C3G and IC-MPGN expands the company's portfolio into potentially a $1 billion addressable market.
Apellis Pharmaceuticals has faced challenges, including an aborted IPO in 2016 and a safety scare related to SYFOVRE in 2023 that caused stock volatility. The company also navigated a negative opinion from the European Medicines Agency for SYFOVRE, with a decision pending, and faces competition in the GA market.
Initial Public Offering Hurdles
An initial $86 million IPO attempt in 2016 was withdrawn before the company secured venture capital funding.
Navigating Regulatory and Safety Concerns
The company addressed a safety scare concerning SYFOVRE in 2023 and is awaiting a final decision from the EMA after an initial negative opinion.
Competitive Market Landscape
Apellis faces competition in the geographic atrophy market from other pharmaceutical companies, requiring continuous strategic focus.
Financial Performance and Investment
The company reported net losses in the first two quarters of 2025, reflecting ongoing research and development and commercialization expenses, as detailed in the Marketing Strategy of Apellis Pharmaceuticals.
Apellis Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Apellis Pharmaceuticals?
Apellis Pharmaceuticals has a history marked by significant growth and strategic advancements in its mission to treat rare diseases. From its founding, the company has focused on developing innovative therapies, achieving key regulatory approvals and expanding its commercial reach.
| Year | Key Event |
|---|---|
| 2009 | Apellis Pharmaceuticals was founded by Cedric Francois and Pascal Deschatelets in Louisville, Kentucky, marking the beginning of its journey. |
| 2010 | The company expanded its operations by establishing a research and development hub in Waltham, Massachusetts. |
| 2017 | Apellis Pharmaceuticals was listed on NASDAQ under the ticker APLS on November 9, signifying a major step in its public market presence. |
| 2021 | The U.S. Food and Drug Administration (FDA) approved EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). |
| 2023 | SYFOVRE (pegcetacoplan injection) received FDA approval for geographic atrophy (GA), offering a new treatment option for this condition. |
| February 2025 | The company reported full year 2024 revenues of $781.4 million, demonstrating a substantial 97% increase year-over-year. |
| July 1, 2025 | A capped royalty purchase agreement was announced with Sobi for up to $300 million, with Apellis receiving $275 million upfront for 90% of ex-U.S. royalties of Aspaveli. |
| July 28, 2025 | The FDA approved EMPAVELI for C3G and primary IC-MPGN, making it the first treatment for these conditions in patients aged 12 and older. |
| July 31, 2025 | Second Quarter 2025 financial results were reported, with total revenue reaching $178.5 million. |
Expanding Therapeutic Reach
Apellis is focused on maximizing the impact of its approved therapies. The U.S. launch of EMPAVELI for C3G and IC-MPGN is anticipated in the second half of 2025.
Pipeline Advancement
The company plans to initiate two Phase 3 trials for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) in the second half of 2025. Analysts predict EMPAVELI could achieve blockbuster status in these new indications.
Commercial Growth Projections
SYFOVRE is projected to see low to mid-single-digit quarterly growth in injections for the remainder of 2025. This growth is a key component of the company's overall business evolution.
Financial Stability and Profitability Path
With a cash position of $370 million as of June 30, 2025, Apellis anticipates funding its business to sustainable profitability by late 2026. This financial outlook supports its Target Market of Apellis Pharmaceuticals and ongoing research endeavors.
Apellis Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Apellis Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Apellis Pharmaceuticals Company?
- How Does Apellis Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Apellis Pharmaceuticals Company?
- What are Mission Vision & Core Values of Apellis Pharmaceuticals Company?
- Who Owns Apellis Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Apellis Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.